Canaloplasty: First day microhyphaema

Article

Potentially a predictive factor for surgical success.

In a prospective, non-randomized study, my colleagues and I evaluated predictive factors for success in canaloplasty.10 The study group included 47 primary open angle glaucoma (POAG) patients with a mean IOP before surgery of 26.8 mmHg ± 5.2 (SD). The mean followup time was 20.6 months ± 8.3 (SD). The mean IOP was 8.4 mmHg ± 4.2 (SD) 1 day after surgery and 12.7 mmHg ± 1.7 (SD) at 24 months.

In a post-hoc analysis, there was no difference between patients with microhyphaema, compared to those without microhyphaema in regard to age, preoperative IOP, glaucomatous damage, number of medications and even in regard to day 1 IOP. However, the lower the target IOP after surgery was defined, the greater the differences in the complete success rates were between the two groups. For instance, the complete success rate in the eyes with microhyphaema was 87% compared to 21% in non-microhyphaema eyes for a target IOP under 16 mmHg, whereas it was 97% versus 71% respectively, for a target IOP less than 21 mmHg. Of note, eyes without microhyphaema required more frequent and earlier laser goniopuncture than eyes with microhyphaema (p < 0.001).

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.